Morten Schou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4440747/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation, 2022, 145, 158-169.	1.6	18
2	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation, 2022, 145, 87-89.	1.6	28
3	The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker). Cardiovascular Diabetology, 2022, 21, 34.	6.8	10
4	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation, 2022, 146, 438-449.	1.6	53
5	MO466: Impact of Renal Insufficiency on Choice of Rhythm or Rate Control in Atrial Fibrillation and Subsequent Effects on Cardiovascular and Mortality Outcomes. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
6	Sodiumâ€Glucose Cotransporterâ€⊋ Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives. Basic and Clinical Pharmacology and Toxicology, 2022, , .	2.5	1
7	MO445: Implications of Cardiac Biomarkers in Patients With Renal Insufficiency on Probability of Coronary Angiography and Subsequent Cardiovascular Outcomes. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
8	The Effect of Empagliflozin on Contractile Reserve in Heart Failure: Prespecified Sub-Study of a Randomized, Double-Blind, and Placebo-Controlled Trial. American Heart Journal, 2022, 250, 57-57.	2.7	1
9	Incidence rates of dilated cardiomyopathy in adult first-degree relatives versus matched controls. IJC Heart and Vasculature, 2022, 41, 101065.	1.1	5
10	The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 × 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with chronic heart failure and diabetes or prediabetes (Met-HeFT). American Heart Journal, 2021, 231, 137-146.	2.7	21
11	Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 106-116.	11.4	80
12	Sex-Specific Prevalence, Incidence, andÂMortality Associated With AtrialÂFibrillation in HeartÂFailure. JACC: Clinical Electrophysiology, 2021, 7, 1366-1375.	3.2	10
13	Abstract P058: Risk Of Heart Failure In Type 2 Diabetes Has Decreased Over Time - A Danish Nationwide Cohort Study. Circulation, 2021, 143, .	1.6	0
14	Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). Circulation, 2021, 143, 2208-2210.	1.6	8
15	Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial. Journal of the American Heart Association, 2021, 10, e020418.	3.7	12
16	Socioeconomic Disparities in Referral for Invasive Hemodynamic Evaluation for Advanced Heart Failure: A Nationwide Cohort Study. Circulation: Heart Failure, 2021, 14, e008662.	3.9	10
17	Longâ€Term Mortality Associated With Use of Carvedilol Versus Metoprolol in Heart Failure Patients With and Without Type 2 Diabetes: A Danish Nationwide Cohort Study. Journal of the American Heart Association, 2021, 10, e021310.	3.7	2
18	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. International Journal of Cardiovascular Imaging, 2021, , 1.	1.5	6

Morten Schou

#	Article	IF	CITATIONS
19	Rate of Heart Failure Following Atrial Fibrillation According to Presence of Family History of Dilated Cardiomyopathy or Heart Failure: A Nationwide Study. Journal of the American Heart Association, 2021, 10, e021286.	3.7	4
20	Lifetime Risk of Heart Failure and Trends in Incidence Rates Among Individuals With Type 2 Diabetes Between 1995 and 2018. Journal of the American Heart Association, 2021, 10, e021230.	3.7	2
21	Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction. New England Journal of Medicine, 2021, 385, 1845-1855.	27.0	130
22	Abstract 10837: Prognostic Importance of Atrial Fibrillation in Heart Failure According to Time Elapsed Since Diagnosis. Circulation, 2021, 144, .	1.6	0
23	Abstract 10629: Effect of Empagliflozin on Blood Volume Redistribution in Patients with Chronic Heart Failure and Reduced Ejection Fraction. Circulation, 2021, 144, .	1.6	0
24	Abstract 10875: Long-Term Mortality Associated with Use of Carvedilol vs Metoprolol in Heart Failure Patients with and Without Type 2 Diabetes. Circulation, 2021, 144, .	1.6	0
25	Abstract 10903: Cardiovascular Morbidity Associated with Monoclonal Gammopathy of Undetermined Significance - A Danish Nationwide Study. Circulation, 2021, 144, .	1.6	0
26	<p>Identification of Patients with New-Onset Heart Failure and Reduced Ejection Fraction in Danish Administrative Registers</p> . Clinical Epidemiology, 2020, Volume 12, 589-594.	3.0	17
27	Coronary risk of patients with valvular heart disease: prospective validation of CT-Valve Score. Open Heart, 2020, 7, e001380.	2.3	0
28	Abstract 16546: Pre-Pregnancy Body Mass Index and Risk of Peripartum Cardiomyopathy and Heart Failure in the Years Following Delivery. Circulation, 2020, 142, .	1.6	0
29	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.	27.0	4,108
30	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). BMJ Open, 2019, 9, e029098.	1.9	3
31	Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. BMC Cardiovascular Disorders, 2016, 16, 117.	1.7	21
32	Incidence of cancer in patients with chronic heart failure: a longâ€ŧerm followâ€up study. European Journal of Heart Failure, 2016, 18, 260-266.	7.1	158
33	Prevalence and significance of troponin elevations in patients without acute coronary disease. International Journal of Cardiology, 2016, 222, 819-825.	1.7	33
34	Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: A nationwide propensity score matched study. International Journal of Cardiology, 2016, 221, 944-950.	1.7	12
35	Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction. PLoS ONE, 2016, 11, e0157167.	2.5	42
36	Iron deficiency: Prevalence and relation to cardiovascular biomarkers in heart failure outpatients. International Journal of Cardiology, 2015, 195, 143-148.	1.7	20

Morten Schou

#	Article	IF	CITATIONS
37	The effect of heparin on pregnancy associated plasma protein-A concentration in healthy, non-pregnant individuals. Clinical Biochemistry, 2015, 48, 757-761.	1.9	2
38	The Influence of Diabetes Mellitus on Midregional Proadrenomedullin Concentrations and Prognostic Value in Heart Failure Outpatients. Journal of Cardiac Failure, 2015, 21, 250-257.	1.7	5
39	Effect of extended followâ€up in a specialized heart failure clinic on adherence to guideline recommended therapy: <scp>NorthStar</scp> Adherence Study. European Journal of Heart Failure, 2014, 16, 1249-1255.	7.1	21
40	Influence of renal impairment on myocardial function in outpatients with systolic heart failure: An echocardiographic and cardiac biomarker study. International Journal of Cardiology, 2014, 177, 942-948.	1.7	6
41	αâ€Defensins and outcome in patients with chronic heart failure. European Journal of Heart Failure, 2012, 14, 387-394.	7.1	22